Drug Development ProgressPhase 2/3 of the drug development is planned to initiate, indicating progress in the company's pipeline.
Market OpportunitySilexion announced additional highly positive preclinical data finding SIL-204 demonstrated 97% tumor growth inhibition in a previously untested KRAS mutated line and successfully showed inhibition in both pancreatic and colorectal cancers.
Therapeutic PotentialSilexion’s siRNA modality has shown an ability to target a broad range of KRAS mutations, potentially making it an ideal therapy for patients compared to current KRAS inhibitors, which only target G12C and have many safety issues.